Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hikma Looks To Be Partner Of Choice In MENA Region Via Acquisition Of Promopharm

This article was originally published in PharmAsia News

Executive Summary

Jordanian drug maker Hikma Pharmaceuticals PLC acquired 63.9% of Moroccan branded generics firm Promopharm SA Oct. 3 in a cash deal worth $111.2 million. The acquisition gives Hikma access to the fourth largest pharmaceutical market in the Middle East and North Africa, additional manufacturing capacity and capability, and a perhaps stronger claim to its goal of being a partner of choice for multinationals across the MENA region
Advertisement

Related Content

Jordan’s Hikma Sails On Strong Winds From Injectables, But Generics Lag
Jordan’s Hikma Continues Buying Spree In MENA With Egypt Acquisition
Quintiles Continues Eastward Push, Looks To Russia And Middle East For Growth
AiFD Vice Chairman Engin Guner On Price Cuts In Turkey And Mounting Pressure On Industry: An Interview With PharmAsia News (Part 2 of 2)
Lilly Among MNCs Scouting In Turkey For Local Partners As GMP Inspection Backlog Continues
Lilly Among MNCs Scouting In Turkey For Local Partners As GMP Inspection Backlog Continues
As Arab Spring Stabilizes, Hikma Sees Improved Results And Better Position
As Arab Spring Stabilizes, Hikma Sees Improved Results And Better Position
Jordanian Drug Maker Buys Baxter Injectable Business, Becomes Second Largest In U.S.
West-Ward Parent Hikma Acquires Egypt’s Alkan Pharma
Advertisement
UsernamePublicRestriction

Register

SC076614

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel